“Our study reveals that a significant portion of patients at the extremes of older age still derive benefit from the VEN-HMA regimen – which is the standard of care for older AML patients and those who are ineligible to receive intensive chemotherapy,” said Justin Watts, M.D., chief of the Leukemia Section at Sylvester Comprehensive Cancer Center.